Jumpcan subsidiary secures lidocaine gel patch drug registration

Hubei Jumpcan Pharmaceutical Co., Ltd. announced today that its wholly-owned subsidiary, Shaanxi Dongke Pharmaceutical Co., Ltd., has received a drug registration certificate from the National Medical Products Administration for Lidocaine Cataplasms. This approval adds a chemical drug, classified as Category 3, to the company's product line for the symptomatic relief of post-herpetic neuralgia on unbroken skin.

Lidocaine Cataplasms, a topical patch containing 700mg of lidocaine per patch (14.0cm × 10.0cm), is approved for 18 months, with the approval valid until September 8, 2030. The product's total research and development expenditure amounted to approximately CNY 17,492,300 (unaudited), which has been fully expensed.

The company anticipates this new registration will positively impact its future development by enriching its product offerings. As of 2024, the market for lidocaine gel patches in Chinese urban public hospitals reached sales of CNY 64,750,000. However, the company also cautioned investors about potential risks from market development cycles, policy changes, and procurement impacts.